Sudarshan Pharma Industries Limited has announced a postal ballot process to seek shareholder approval for the appointment of Dr. Vijay Ojha as Non-Executive Independent Director. The company issued the notice on December 9, 2025, with the cut-off date for eligible voting set as December 5, 2025.

Director Appointment Details

Dr. Vijay Ojha was initially appointed as Additional Director (Non-Executive Independent) on October 18, 2025, based on the recommendation of the Nomination Remuneration Committee. The postal ballot seeks formal shareholder approval for his appointment as Independent Director for a five-year term.

Professional Background

Dr. Vijay Ojha brings over 30 years of industrial experience in the pharmaceutical sector, specifically in API and formulation development, scale-up commercialization. He holds a Doctorate of Philosophy (PhD) from Central Drug Research Institute, Lucknow. His professional experience includes associations with prominent pharmaceutical companies such as Lupin Limited, Sun Pharmaceuticals Limited, IPCA Laboratories Limited, and Flavine Inc., USA.

E-Voting Process and Timeline

The company has engaged National Securities Depository Limited (NSDL) to provide remote e-voting facility to shareholders. The voting process will be conducted entirely through electronic means, with no physical postal ballot forms being distributed.

Compliance and Governance

The postal ballot notice has been sent electronically to all members whose email addresses are registered with the company or depositories. Mr. Vishal Manseta (Membership No.: 25183, COP No.: 8981), Company Secretary in Practice, has been appointed as Scrutinizer for conducting the postal ballot process.

Dr. Ojha has submitted declarations confirming his independence as per Section 149(6) of the Companies Act, 2013, and Regulation 16(1)(b) of SEBI Listing Regulations. He currently holds no directorships in other companies and has no shareholding in Sudarshan Pharma Industries.

Committee Memberships

Upon appointment, Dr. Ojha will serve as a member of key board committees:

• Stakeholders Relationship Committee
• Nomination Remuneration Committee

The board considers Dr. Ojha's appointment desirable and in the company's interest, given his extensive pharmaceutical industry experience and expertise in API and formulation development.

Sudarshan Pharma Industries Limited (SPIL) has announced two strategic appointments to bolster its business operations and development teams. The company has brought on board experienced professionals to lead key divisions, signaling a focus on growth and operational excellence.

New Leadership Appointments

Rahul Pandey: Driving Global Healthcare Expertise

Rahul Pandey joins SPIL with over 15 years of experience in the global healthcare industry. His appointment as President of Business Operations & Development for the Excipients & API Division brings valuable expertise to the company. Pandey's background includes:

• Driving growth and operational excellence across APIs, excipients, granules, and specialty ingredients
• Building business presence in key markets including Bangladesh, MENA region, Korea, Indonesia, and China
• Combining global business acumen with deep technical understanding and operational discipline

Pandey's experience with industry leaders such as Pfizer Limited, Mylan Limited, and others positions him well to contribute to SPIL's growth strategies in the pharmaceutical ingredients sector.

Mayank Vyas: Bringing Diverse Industry Experience

Mayank Vyas steps into the role of President - Business Development Manager, bringing over 20 years of experience in marketing and HR across various industries. His diverse background includes:

• Expertise in manufacturing quality and understanding of manufacturing processes
• Experience in problem-solving and quality improvement in manufacturing settings
• Skills in identifying root causes of non-conformity and implementing corrective actions

Vyas's multifaceted experience, spanning construction equipment, tiles, pharma machinery, and chemicals, is expected to bring a fresh perspective to SPIL's business development initiatives.

Corporate Governance and Approval Process

The appointments of both Pandey and Vyas were made following a structured approval process:

1. Initial review and approval by the Nomination Remuneration Committee
2. Final approval by the Board of Directors of Sudarshan Pharma Industries Limited

This process underscores SPIL's commitment to corporate governance and strategic decision-making in its leadership appointments.

The addition of these seasoned professionals to Sudarshan Pharma Industries Limited's leadership team aligns with the company's vision for growth and operational enhancement. As the pharmaceutical industry continues to evolve, the diverse expertise of Pandey and Vyas is expected to play a crucial role in shaping SPIL's future strategies and market position.